Literature DB >> 35513610

Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases.

James E Lapinski1, Alok A Khorana2, Lisa Rybicki3, Canan Firat4, Hwajeong Lee5, Kathryn Piotti6, Eugene H Lewis7, Michael McNamara2, Vikram Deshpande8, Jinru Shia4, Deepa T Patil9,10.   

Abstract

Lymph nodes with acellular mucin harvested from treated colorectal cancers (CRC) are staged as pN0. However, there is variability among pathologists while reporting the pN stage when acellular mucin is found within nodes of untreated CRCs. While the UICC guidelines suggest staging them as pN1, the AJCC and CAP do not offer any recommendations. In order to characterize their clinicopathologic features and outcome, we compared 16 untreated CRCs (study group; mean age: 68 years) harboring nodes with acellular mucin with 34 pN0 and 25 pN1 untreated CRC controls. All tumors were unifocal; 12 (75%) were right-sided lesions. Most cases (75%) showed one node with acellular mucin (range: 1-3). MMR-deficient tumors were significantly more common in the study group (83%) compared to pN0 (33%; p = 0.006) and pN1 controls (8%; p < 0.001). The overall survival of study group patients was closer to pN0 compared to pN1 controls; however, this difference was not statistically significant. In conclusion, untreated CRC that harbor acellular mucin within lymph nodes commonly present as right-sided, MMR-deficient tumors in older women that show a non-mucinous phenotype. While the limited number of cases precludes us from making any formal recommendations about staging, we suggest that the finding of acellular mucin in a node should prompt evaluation of deeper levels (with or without cytokeratin immunohistochemistry) and submission of all pericolonic fat for additional lymph node harvest. Whether acellular mucin in nodes of untreated CRCs is related to the indolent biology of the disease, a robust local immune response or MMR deficiency requires further investigation.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Acellular mucin; Colon cancer; Lymph nodes; Untreated

Mesh:

Substances:

Year:  2022        PMID: 35513610     DOI: 10.1007/s00428-022-03332-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

Review 1.  Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management.

Authors:  Aaron J Franke; Hiral Parekh; Jason S Starr; Sanda A Tan; Atif Iqbal; Thomas J George
Journal:  Clin Colorectal Cancer       Date:  2017-06-27       Impact factor: 4.481

2.  How do we stage acellular mucin in lymph nodes of colorectal cancer specimens without neo-adjuvant therapy?

Authors:  Keen S Foong; Ami Mishra; Richard Guy; Lai M Wang; Neil A Shepherd
Journal:  Histopathology       Date:  2016-05-05       Impact factor: 5.087

3.  Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma.

Authors:  Anne Rullier; Christophe Laurent; Veronique Vendrely; Brigitte Le Bail; Paulette Bioulac-Sage; Eric Rullier
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

4.  On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study.

Authors:  Bernd Holleczek; Silvia Rossi; Agius Domenic; Kaire Innos; Pamela Minicozzi; Silvia Francisci; Monika Hackl; Nora Eisemann; Hermann Brenner
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

5.  Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy.

Authors:  Jinru Shia; Martine McManus; Jose G Guillem; Tobias Leibold; Qin Zhou; Laura H Tang; Elyn R Riedel; Martin R Weiser; Philip B Paty; Larissa K Temple; Garrett Nash; Konstantin Kolosov; Bruce D Minsky; W Douglas Wong; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

6.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

Authors:  Daniel G Haller; Paul J Catalano; John S Macdonald; Mark A O'Rourke; Michael S Frontiera; Don V Jackson; Robert J Mayer
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation.

Authors:  Kerrington D Smith; Dongfeng Tan; Prajnan Das; George J Chang; Kiran Kattepogu; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

8.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel Sargent; Alberto Sobrero; Axel Grothey; Michael J O'Connell; Marc Buyse; Thierry Andre; Yan Zheng; Erin Green; Roberto Labianca; Chris O'Callaghan; Jean Francois Seitz; Guido Francini; Daniel Haller; Greg Yothers; Richard Goldberg; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

9.  Challenges with colorectal cancer staging: results of an international study.

Authors:  Dipti M Karamchandani; Runjan Chetty; Tonya S King; Xiuli Liu; Maria Westerhoff; Zhaohai Yang; Rhonda K Yantiss; David K Driman
Journal:  Mod Pathol       Date:  2019-08-05       Impact factor: 7.842

10.  The lymph node status as a prognostic factor in colon cancer: comparative population study of classifications using the logarithm of the ratio between metastatic and nonmetastatic nodes (LODDS) versus the pN-TNM classification and ganglion ratio systems.

Authors:  Carlos Fortea-Sanchis; David Martínez-Ramos; Javier Escrig-Sos
Journal:  BMC Cancer       Date:  2018-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.